Corteva, Inc.
At today's price, Corteva, Inc. (CTVA) is priced for +12.5% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
The defining feature is the seed moat: Corteva runs a 17.2% operating margin on a portfolio anchored by thousands of germplasm and biotechnology patents, and only the growth-DCF method reaches the price. The market is paying a durability premium the static frames cannot capture. The transformational catalyst is the Q4 2026 separation into two companies, a high-margin seed business named Vylor and a standalone crop-protection company. The split is the explicit attempt to surface the value SOTP a
Is CTVA overvalued? See what's priced in →
1,436 institutional managers reported holding CTVA in 13F filings for the quarter ended 2026-03-31. Together they hold about 85% of the company; the top 10 hold 49%. 160 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 18.1M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (4.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CTVA has cut its share count 8.8% over the past five years, spending $4.49B on repurchases. It pays a dividend, and has for 3 years running, raised 2 years straight; the current rate is $0.70 a share annually. Cash returned over the past three years: $1.28B in dividends and $2.75B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CTVA over the trailing three years: 2023: 5 buys totaling $385k. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CTVA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | +0.2% | -10.7% |
| 2023-11-10 | -9.7% | +5.9% |
| 2024-02-09 | +18.0% | +0.3% |
| 2024-05-03 | +6.0% | -8.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CTVA's latest 8-K filings: 2026-06-29 (items 5.02, 7.01, 9.01); 2026-05-05 (items 2.02, 9.01); 2026-05-01 (items 5.07); 2026-04-14 (items 5.02, 7.01, 9.01); 2026-02-03 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.